Public Health Watchdog Warns Fresenius GranuFlo® and NaturaLyte® Dialysis Products Linked to Potentially Deadly Heart Complications

Share Article

Public Health Watchdog is warning consumers about the potentially fatal risks associated with GranuFlo® and NaturaLyte®, two dialysis products manufactured by Fresenius Medical Care. The U.S. Food and Drug Administration (FDA) has issued a Class I recall of GranuFlo® and NaturaLyte®, warning that alkali dosing errors with these products may lead to metabolic alkalosis, cardiac complications and other serious adverse events, including death.

Public Health Watchdog, a media outlet created to protect and warn consumers about the dangers of defective products, is warning the public that Fresenius’ GranuFlo® and NaturaLyte® dialysis products are associated with potentially deadly complications. According to the U.S. Food and Drug Administration (FDA), dosing errors with these products can contribute to significant risk factors for cardiac arrest. Earlier this year, the New York Times reported that Fresenius Medical Care knew about the risks related to GranuFlo and NaturaLyte, but did not warn the public until the discovery of an internal memo.

In June, the FDA issued a Class I recall of Fresenius Medical Care North America Naturalyte Liquid Acid Concentrate and Naturalyte GranuFlo (powder) Acid Concentrate, warning that “Inappropriate prescription of these products can lead to a high serum bicarbonate level in patients undergoing hemodialysis.” GranuFlo and NaturaLyte both contain acetate, which ultimately converts to bicarbonate in the blood; this helps neutralize the acidity of the blood in dialysis patients. However, GranuFlo and NaturaLyte contain higher levels of acetate compared to other competing products, and failing to take this into account can lead to excess bicarbonate or metabolic alkalosis. In their recall notice, the FDA warned that metabolic alkalosis is associated with low blood pressure, hypokalemia (low potassium), hypoxemia (low blood oxygen), hypercapnia (excess carbion dioxide in the blood) and cardiac arrhythmia. These factors can lead to cardiac arrest and death, the agency stated.

According to the New York Times, Fresenius knew that dosing errors related to GranuFlo and NaturaLyte could lead to death and other serious health consequences. In fact, the company sent out an internal memo, dated last November, regarding the issue. The memo not only acknowledged the potential for metabolic alkalosis and cardiac death associated with GranuFlo and NaturaLyte, but also pointed out that 941 patients experienced cardiac arrest in Fresenius clinics in 2010. The memo called the findings “troubling” and advised doctors to adjust the alkalinity of the blood accordingly.

Fresenius did not notify the public, outside consumers or the FDA about the risks associated with GranuFlo and NaturaLyte until prompted by the FDA, who received an anonymous copy of the internal memo. The company did not issue a letter to its consumers until late March, stating that “Recent analyses performed using FMCNA hemodialysis (HD) patient safety data confirms that alkalosis is a significant risk factor associated with cardiopulmonary (CP) arrest in the dialysis unit.” The letter did not mention the 941 patients who suffered from cardiac arrests in Fresenius clinics.

About Public Health Watchdog

Public Health Watchdog is a media outlet created to provide consumers with up-to-date information about defective drugs and medical devices that could endanger their health. For more information on Fresenius’ GranuFlo® and NaturaLyte® dialysis products, as well as other dangerous drugs and medical devices, please visit Public Health Watchdog today.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Gary Falkowitz, Managing Attorney
Follow us on
Visit website